Kinnate Biopharma Stock Total Debt

KNTEDelisted Stock  USD 2.96  0.27  8.36%   
Kinnate Biopharma fundamentals help investors to digest information that contributes to Kinnate Biopharma's financial success or failures. It also enables traders to predict the movement of Kinnate Stock. The fundamental analysis module provides a way to measure Kinnate Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kinnate Biopharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kinnate Biopharma Company Total Debt Analysis

Kinnate Biopharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Total Debt

 = 

Bonds

+

Notes

More About Total Debt | All Equity Analysis

Current Kinnate Biopharma Total Debt

    
  3.17 M  
Most of Kinnate Biopharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kinnate Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Competition

Based on the latest financial disclosure, Kinnate Biopharma has a Total Debt of 3.17 M. This is 99.88% lower than that of the Biotechnology sector and 99.02% lower than that of the Health Care industry. The total debt for all United States stocks is 99.94% higher than that of the company.

Kinnate Total Debt Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kinnate Biopharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics of similar companies.
Kinnate Biopharma is currently under evaluation in total debt category among its peers.

Kinnate Fundamentals

About Kinnate Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk